BDPT
BioAdaptives, Inc.0.0278
+0.0035+14.3%
Dec 15, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
333.54KP/E (TTM)
-Basic EPS (TTM)
-0.06Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
BioAdaptives posted Q3 revenue of $4,632, up from zero a year ago, yet posted an operating loss of $265,689 and net loss of $379,502, wider than last year's $37,649 due to $201k adverse change in derivative liabilities fair value. YTD revenue fell to $7,851 from $12,669, with operating loss $794k versus $265k prior, while net loss narrowed to $735k from $527k on debt settlement gains. Cash drained to $59k after $360k operating outflow, offset by $300k Series D proceeds; convertible notes total $359k, all current, with $967k derivatives. No free cash flow disclosed. Massive dilution looms from 144M anti-dilutive equivalents.
10-Q
Q2 FY2025 results
BioAdaptives posted Q2 revenue of $3,219, up sharply from $675 y/y yet still tiny, with gross profit at $1,063 but operating loss widening to $279K from $93K on surging G&A and professional fees to $280K total. Net loss narrowed to $158K from $183K y/y, thanks to $131K gain on derivative liabilities that offset interest; the $122K gap from operating loss stems from that non-op gain. Cash climbed to $211K after $300K from Series D preferred issuance funded $209K operating burn, while $311K convertible notes (in default) and $861K derivatives loom large. Stock comp fueled dilution. PawPa Regen dog treats gained Amazon nod. Controls remain weak.
10-Q
Q1 FY2025 results
BioAdaptives posted no revenue for Q1 ended March 31, 2025, down from $11,994 y/y, with operating loss widening to $249,148 (up 397% y/y) on higher G&A and professional fees, yet net loss narrowed to $197,136 from $306,707 thanks to a $61,659 gain on derivative fair value changes versus a $202,260 loss prior year. Cash drained $97,906 in operations (derived), leaving $39,564 on hand amid $311,000 convertible notes (12%/10% rates, in default) and $991,590 derivative liabilities. Inventory doubled to $40,584 q/q. Products like PawPa Regen dog treats launched post-quarter. Diluted EPS of -$0.02 reconciles to 9,048,725 weighted shares. Controls remain ineffective. Defaults on notes loom.
10-K
FY2024 results
BioAdaptives posted FY2024 revenue of $12,669, down sharply from $28,565 in 2023 as new CEO James Keener canceled the old product line in May, yielding a $899k net loss on 8.2M weighted shares for $(0.11) diluted EPS. Operating expenses jumped to $606k from $240k, driven by G&A and professional fees, while Q4 saw inventory impairment of $81k and full license/patent write-off. Cash climbed to $137k from $61k via preferred stock raises, yet derivative liabilities swelled to $1.1M. New products like Zeranovia™ launch Q2 2025. No revenue covers expenses. Going concern in doubt.
8-K
Zeranovia trial success
BioAdaptives announced promising dosage trial results for Zeranovia™ weight loss product on March 13, 2025, with participants losing 5 to 7 pounds weekly and minimal side effects like mild gastrointestinal discomfort, managed by water or dosage tweaks. All subjects requested next-phase progression. Trials advance now.
IPO
Employees
Sector
Industry
ADIA
Adia Nutrition, Inc.
0.07-0.00
ADTI
Adapti, Inc.
2.03+0.00
ATPC
Agape ATP Corporation
0.09-0.03
BFNH
BioForce Nanosciences Holdings,
0.60+0.07
BHST
BioHarvest Sciences Inc.
5.50+0.30
FRPT
Freshpet, Inc.
63.97+0.41
NATR
Nature's Sunshine Products, Inc
22.38-0.85
NPRFF
NEPRA FOODS INC.
0.10+0.00
RKDA
Arcadia Biosciences, Inc.
3.64-0.03
ZIVO
Zivo Bioscience, Inc.
9.00+0.00